RBC Bioscience

RBC Bioscience Net Debt per Share

The Net Debt per Share of RBC Bioscience (6848.TWO) as of Oct 22, 2026 is 27.84 TWD. In the previous year, Net Debt per Share was 28.48 TWD — a change of -2.25% (lower).

Net Debt per Share

27.84TWD

YoY

-2.25%

Last updated:

Net Debt per Share of RBC Bioscience is 2024 27.84 TWD. Net Debt per Share of RBC Bioscience was 2023 28.48 TWD. It decreases by -2.25% lower compared to the previous year.

The RBC Bioscience Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2018
1.78 TWD
Jan 1, 2019
3.61 TWD
Jan 1, 2020
-4.45 TWD
Jan 1, 2021
26.95 TWD
Jan 1, 2022
28.39 TWD
Jan 1, 2023
28.48 TWD
Jan 1, 2024
27.84 TWD
The RBC Bioscience Net Debt per Share history
YEARNet Debt per ShareYoY
27.84TWD-2.25%
28.48TWD+0.34%
28.39TWD+5.36%
26.95TWD-705.72%
-4.45TWD-223.09%
3.61TWD+103.24%
1.78TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RBC Bioscience Stock analysis

What does RBC Bioscience do? RBC Bioscience Corp manufactures reagents and devices for life science and molecular diagnosis. The company's products include instruments equipped with ultraviolet sterilization systems for nucleic acid purification and disposable reagent strips and tips that work with built-in control programs for different nucleic acid extraction types. The firm developed nucleic acid purification reagents with cellulose-embedded magnetic beads to improve DNA and RNA purity for blood, bacteria, viruses, and forensic examinations. These products are used for future diagnosis, prevention, tracking, and treatment of diseases. The company sells its instruments and reagents to customers in life science and molecular diagnosis sectors. The instruments feature ultraviolet sterilization systems, while the reagents include disposable strips and tips with varying control programs. The reagents with cellulose-embedded magnetic beads are designed for high-purity nucleic acid extraction from diverse samples including blood, bacteria, viruses, and forensic materials. RBC Bioscience Corp's revenue comes from the sale of instruments and reagents. The instruments are sold to laboratories and medical facilities requiring nucleic acid purification systems. The reagents, including the disposable strips and tips, are sold alongside the instruments or separately for ongoing use in molecular diagnosis processes. RBC Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RBC Bioscience stock

Net Debt per Share of RBC Bioscience is 27.84 TWD in 2024.

Net Debt per Share of RBC Bioscience changed from 28.48 TWD to 27.84 TWD, representing a -2.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share RBC Bioscience since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — RBC Bioscience

All Key Metrics — RBC Bioscience